Company news from the 01/16/07 news brief

Share this article:
Genizon BioSciences announced a license and collaboration agreement with Pfizer for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights. Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed. Redi-Direct Marketing has acquired New York-based Dialog Group, including the firm’s Healthcare Dialog division, a developer of relationship marketing and communication programs for the pharmaceutical industry. Financial terms of the deal were not disclosed. CMPMedica has acquired MediReach Healthcare Communications, a Shanghai, China, consultancy providing medical and pharmaceutical marketing services to multinational pharmaceutical companies across China, for an initial payment of $1.1 million and as much as $2.75 million contingent on future performance.
Share this article:

Email Newsletters

More in News

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.